Monkeypox Vaccine And Treatment Market Size to Hit USD 214.79 mn by 2030

According to Nova one advisor, the global Monkeypox Vaccine And Treatment market size is expected to hit around USD 214.79 million by 2030 from valued at USD 85.43 million in 2022 and growing at a CAGR of 10.26% from 2022 to 2030.

Request Free Sample of This Report@

Key Takeaways:

  • Based on product, the drugs segment held the largest share in 2022 owing to ongoing product approvals and increasing demand for antiviral drugs for the treatment
  • The male segment accounted for the largest share in 2022 due to the higher prevalence of infections among men
  • By route of administration, the oral segment dominated the market in 2022 due to the increased demand for oral antiviral drugs for the treatment of monkeypox disease
  • The hospitals segment was the largest segment in 2022. The specialty clinics segment is anticipated to register the fastest growth rate throughout the forecast period
  • Asia Pacific is expected to exhibit the fastest growth rate over the forecast period due to the increased risk of monkeypox infections and increasing awareness about vaccination

Report Scope of the Monkeypox Vaccine And Treatment Market

Report Coverage


Market Size

USD 214.79 million by 2030

Growth Rate

CAGR of 10.26% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year


Forecast Period

2022 to 2030

Segments Covered

 Product, gender, route of administration, end-use And Region

Companies Mentioned

 Bavarian Noric; SIGA Technologies; Chimerix; EMERGENT; Gilead Sciences, Inc.

 Ask here for more customization study@

The growing government initiatives for combating the monkeypox virus threat and a surge in awareness about the disease are the major factors driving the market. Moreover, an increase in R&D activities to develop vaccines and treatments is expected to fuel market growth.

The incidence rate of infection is higher in men as compared to women. According to the CDC’s data of August 2021, the monkeypox virus affected over 2,231 men of age 31 to 35 as compared to 11 women of age 31 to 35. The infection rate of the virus is more common in people between 20 to 50 years of age. Thus, the rising infection rates from the monkeypox virus are anticipated to fuel the demand for novel and effective treatment.

The increasing funding for boosting research activities and expanding manufacturing capacities of vaccine plants is likely to fuel market demand. For instance, in August 2022, the U.S. Department of Health and Human Services announced a funding of USD 11 million for providing support to fill and finish the manufacturing of JYNNEOS vaccine approved for preventing monkeypox and smallpox at GRAM, Michigan. This funding will assist GRAM to purchase extra equipment for JYNNEOS production.

Moreover, in July 2022, the pandemic institute awarded funding of around USD 580,049 to Liverpool researchers for managing the global threat of monkeypox. The funding is awarded for promoting research activities for understanding the stigma around the disease and developing new treatment regimens.

Furthermore, various strategic initiatives undertaken by the leading market players to strengthen their portfolio and market footprint are expected to facilitate market expansion. For instance, in August 2022, Bavarian Nordic A/S announced an agreement with Pan American Health Organization to boost equitable access to the Bavarian Nordic A/S monkeypox vaccine for countries in the Caribbean and Latin America. The vaccine delivery is likely to commence in the month of September.

In addition, in May 2022, SIGA Technologies, Inc. announced that its IV formulation TPOXX (tecovirimat) received U.S. FDA approval for the treatment of smallpox. The intravenous formulation is an alternative for patients who cannot swallow the oral formulation of the TPOXX. The IV formulation of TPOXX is also being used to manage the symptoms of monkeypox in the U.S.

However, the chances of side effects from the vaccine may hinder the market growth in the coming years. Some of the common side effects associated with the monkeypox vaccine include induration, muscle pain, swelling, nausea, and itching, among others.

Product Insights

The drugs segment led the market in 2022 with a share of over 70.7%. Increasing patient base of monkeypox disease, increasing usage of antiviral drugs, and high treatment cost for the symptomatic treatment of the disease are some key factors fueling the growth. For instance, in July 2022, the U.K. approved SIGA’s tecovirimat (oral) for the treatment of monkeypox and other indications in adults and children with body weights above 13 kg. The drug also has approval in other European countries for the treatment of monkeypox disease.

The vaccine segment is expected to grow at a significant rate over the forecast period. Factors such as increasing adoption of vaccines for monkeypox infection, rising awareness regarding vaccination, and extensive R&D efforts to develop novel products are expected to support segment growth. Moreover, various government initiatives for making vaccines available are anticipated to fuel segment growth. For instance, in August 2022, the HHS facilitated an agreement between Grand River Aseptic Manufacturing and Bavarian Nordic to establish the first finish and fill line of the JYNNEOS vaccine in the U.S.

Gender Insights

The male segment dominated the market in 2022 with a revenue share of over 90.4%. The higher prevalence of monkeypox among men as compared to women is the major factor driving the segment demand. For instance, according to the CDC, the virus affected almost 13,826 males. Thus, the higher prevalence of infection in men than women is likely to augment segment growth.

Moreover, a higher number of vaccine doses among the male population has increased the segment share. For instance, till 6 September 2022, more than 91% of total JYNNEOS vaccine doses are administered to the male population in the U.S.

End-use Insights

Hospitals captured the largest revenue share of over 75.7% in 2022 and are projected to maintain their position during the projected period. Higher hospitalizations owing to the monkeypox outbreak and increased demand for therapeutic products in hospitals for symptomatic treatment are expected to fuel growth. Moreover, various initiatives undertaken by government bodies such as the American Hospital Association and the Department of Health and Human Services to improve the treatment and continuous monitoring of patients’ health having monkeypox infections are increasing the patient base in the hospital.

The specialty clinics segment is likely to be the fastest-growing segment over the forecast period. The growth of the segment is governed by rising awareness among people about immunization and high infection rates of the virus.

Route Of Administration Insights

In 2022, the oral segment held the largest market share of over 66.0%. The higher demand for oral route therapeutics, ease of administration, and cost-effectiveness of oral products are some of the factors contributing to the segment expansion. Moreover, most common drugs such as tecovirimat and brincidofovir are administered orally.

The injectable segment is projected to grow at a double-digit rate over the forecast period. Increasing demand for vaccines, higher bioavailability of injectable products, rapid onset of action of treatment products, and less possibility of first-pass metabolism in case of intravenous products are some of the factors contributing to the segment growth.

Furthermore, the injectable route helps to optimize the immunogenicity of the vaccine and reduce adverse reactions at the site of injection. An example of a vaccine given by injectable route is JYNNEOS, which is administered by subcutaneous route in two doses (0.5 mL) 4 weeks apart.

Regional Insights

North America dominated the market with a revenue share of over 40.9% in 2022 due to the presence of a large number of leading players, coupled with various strategic initiatives undertaken by them. Moreover, the increase in disease prevalence and rising awareness among people regarding vaccination are expected to spur regional market expansion. In addition, favorable support from the government and higher R&D investments are anticipated to provide lucrative growth opportunities for the North American region.

Asia Pacific is projected to witness the fastest growth over the forecast period. The increasing number of monkeypox infections and increasing R&D for developing prevention and therapeutic options are some of the primary factors driving the market. Increasing prevalence of infection in Asia Pacific countries such as Australia, Singapore, and India is expected to fuel the market growth.

Some of the prominent players in the Monkeypox Vaccine And Treatment Market include:

  • Bavarian Nordic
  • SIGA Technologies
  • Chimerix
  • Gilead Sciences, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Monkeypox Vaccine And Treatment market

  • Product
    • Vaccine
      • JYNNEOS/ Imvanex
      • Smallpox Vaccine
      • Others           
    • Drugs
      • Tecovirimat
      • Brincidofovir
      • Cidofovir
      • Others
    • Vaccinia Immune Globulin (VIG)
  • Gender
    • Male
    • Female
    • Others
  • Route of Administration
    • Oral
    • Injectable
  • End-use
    • Hospitals
    • Specialty Clinics
    • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Full Report is Ready | For Purchase Inquiry@

You can place an order or ask any questions, please feel free to| +1 9197 992 333






Back to news